FDA Clearance Tracker · P150010-S005
HYMOVIS ONE
Last checked: Nov 20, 2026Latest source record: Apr 9, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Apr 9, 2025
Approved
Time to decision
107 days
Received Dec 23, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150010-S005
- Device name
- HYMOVIS ONE
- Applicant
- Fidia Farmaceutici
- Applicant location
- Abano Terme
- Received
- Dec 23, 2024
- Decided
- Apr 9, 2025
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150010
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
HYMOVIS® ONE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).
Source documents
Other decisions for Fidia Farmaceutici
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K191052 · Decided Jan 9, 2020 · 265 days after receipt
Device type: Lubricant, Personal (NUC) · Obstetrics & Gynecology
- TRILURONPMA
P180040 · Decided Mar 26, 2019 · 180 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
K150883 · Decided Sep 1, 2015 · 152 days after receipt
Device type: Lubricant, Personal (NUC) · Obstetrics & Gynecology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.